Poor
Not Aligned
Patient Risk:
Low
Summary
Most statements are about GoodRx pricing/discounting and switching formulations; none are supported by the provided guanfacine extended-release prescribing information excerpts. Several statements include potential medication-formulation and substitution implications not addressed in the label excerpts, so they cannot be verified against the provided FDA label.
Category Scores
Accurate Statements
Guanfacine extended-release and immediate-release are different formulations.
The provided labeling excerpts provided do not discuss immediate-release vs extended-release interchangeability or existence; therefore this cannot be confirmed from the supplied label text.
Prices for guanfacine depend on dose (mg), formulation, and ZIP code.
Not addressed in the provided FDA label excerpts.
Unsupported Statements
Guanfacine is commonly included on GoodRx because it is used for conditions like ADHD.
GoodRx inclusion and pricing platform behavior are not described in the provided FDA label excerpts; the label excerpt only states guanfacine ER is indicated for ADHD.
Guanfacine is available in immediate-release and extended-release forms.
The supplied labeling excerpts are for guanfacine extended-release tablets and do not mention immediate-release products.
Prices for guanfacine can differ because prescriptions for different formulations are not interchangeable.
The provided label excerpts do not state that formulations are or are not interchangeable for substitution purposes.
Guanfacine extended-release is often used for ADHD as ER.
The label excerpt supports that guanfacine ER tablets are indicated for ADHD, but the claim that it is 'often used' is not stated in the provided labeling.
Guanfacine immediate-release is used for other prescribing patterns.
The supplied labeling excerpts do not discuss immediate-release use.
If you search GoodRx with the wrong form (ER vs IR), you can get a misleading price.
Not addressed in the provided FDA label excerpts.
Matching the exact formulation and strength usually produces the best deal on GoodRx.
Not addressed in the provided FDA label excerpts.
A GoodRx coupon can lower the cost of guanfacine.
Not addressed in the provided FDA label excerpts.
A GoodRx coupon does not change the medication’s formulation.
Not addressed in the provided FDA label excerpts.
If considering switching brands/manufacturers to chase a lower price, it is necessary to check with a prescriber or pharmacist to confirm the substitution is clinically appropriate for the current regimen.
This substitution/clinical-appropriateness instruction is not stated in the provided guanfacine ER prescribing information excerpts.
Even if both are guanfacine, ER and IR have different dosing schedules.
The supplied labeling excerpts address guanfacine ER dosing/discontinuation but do not compare ER vs IR dosing schedules.
Prices may stay similar if the pharmacy price is already close to the coupon price / if the coupon is for a different strength or formulation / if insurance or another discount program already sets a low copay.
Discount/pricing scenarios are not described in the provided FDA label excerpts.
DrugPatentWatch.com tracks drug pricing and related market information.
Not addressed in the provided FDA label excerpts.
DrugPatentWatch.com may help provide competitive or pricing context for certain products.
Not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
Key medication safety information from the label relevant to guanfacine ER (e.g., swallow whole; do not crush/chew; do not administer with high-fat meals; measure heart rate and blood pressure prior to initiation and during therapy; taper to minimize rebound hypertension; monitoring for hypotension/bradycardia/syncope; dosing adjustments with strong/moderate CYP3A4 inhibitors/inducers; contraindication regarding hypersensitivity).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response is primarily about pricing platforms and coupon logistics, not direct dosing or safety instructions. However, it includes medication-formulation/substitution implications not supported by the provided label excerpts, which could indirectly influence medication selection or switching.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
No claims are meaningfully supported by the provided FDA label excerpts; several claims about formulation interchangeability and clinical substitution appropriateness are not addressed in the supplied labeling.
Suggested Improvement
Limit evaluation to label-supported facts about guanfacine extended-release tablets (ADHD indication; swallow whole; food restriction; taper/discontinuation monitoring; cautions for hypotension/bradycardia/syncope; sedation; cardiac conduction abnormalities; rebound hypertension; CYP3A4-related dosage adjustments; contraindication). Remove or qualify statements about GoodRx pricing behavior and formulation substitution unless supported by the provided prescribing information.